Literature DB >> 23612854

Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Gianluigi Tanda1, Su Min Li, Maddalena Mereu, Alexandra M Thomas, Aaron L Ebbs, Lauren E Chun, Valeria Tronci, Jennifer L Green, Mu-Fa Zou, Theresa A Kopajtic, Amy Hauck Newman, Jonathan L Katz.   

Abstract

RATIONALE: Dopamine transporter (DAT) conformation plays a role in the effectiveness of cocaine-like and other DAT inhibitors. Cocaine-like stimulants are intolerant to DAT conformation changes having decreased potency in cells transfected with DAT constructs that face the cytosol compared to wild-type DAT. In contrast, analogs of benztropine (BZT) are among compounds that are less affected by DAT conformational change.
METHODS: We compared the displacement of radioligand binding to various mammalian CNS sites, acute stimulation of accumbens shell dopamine levels, and place conditioning in rats among cocaine and four BZT analogs with Cl substitutions on the diphenyl-ether system including two with carboalkoxy substitutions at the 2-position of the tropane ring.
RESULTS: Binding assays confirmed high-affinity and selectivity for the DAT with the BZT analogs which also produced significant stimulation of mesolimbic dopamine efflux. Because BZT analogs produced temporal patterns of extracellular dopamine levels different from those by cocaine (3-10 mg/kg, i.p.), the place conditioning produced by BZT analogs and cocaine was compared at doses and times at which both the increase in dopamine levels and rates of increase were similar to those produced by an effective dose of cocaine. Despite this equilibration, none of the BZT analogs tested produced significant place conditioning.
CONCLUSIONS: The present results extend previous findings suggesting that cocaine-like actions are dependent on a binding equilibrium that favors the outward conformational state of the DAT. In contrast, BZT analogs with reduced dependence on DAT conformation have reduced cocaine-like behavioral effects and may prove useful in development of medications for stimulant abuse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612854      PMCID: PMC3758386          DOI: 10.1007/s00213-013-3109-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys.

Authors:  W L Woolverton; G S Hecht; G E Agoston; J L Katz; A H Newman
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

2.  The rate of intravenous cocaine administration determines susceptibility to sensitization.

Authors:  Anne-Noel Samaha; Yilin Li; Terry E Robinson
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

3.  Ventral striatal anatomy of locomotor activity induced by cocaine, D-amphetamine, dopamine and D1/D2 agonists.

Authors:  S Ikemoto
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

4.  Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.

Authors:  Claus Juul Loland; Lene Norregaard; Thomas Litman; Ulrik Gether
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

5.  The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter.

Authors:  M E Reith; J L Berfield; L C Wang; J V Ferrer; J A Javitch
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

6.  Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Authors:  Maarten E A Reith; Solav Ali; Audrey Hashim; Imran S Sheikh; Naresh Theddu; Narendra V Gaddiraju; Suneet Mehrotra; Kyle C Schmitt; Thomas F Murray; Henry Sershen; Ellen M Unterwald; Franklin A Davis
Journal:  J Pharmacol Exp Ther       Date:  2012-08-15       Impact factor: 4.030

7.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

8.  N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects.

Authors:  Su-Min Li; Theresa A Kopajtic; Matthew J O'Callaghan; Gregory E Agoston; Jianjing Cao; Amy Hauck Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2010-11-18       Impact factor: 4.030

9.  Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.

Authors:  Theresa A Kopajtic; Yi Liu; Christopher K Surratt; David M Donovan; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2010-09-20       Impact factor: 4.030

10.  Behavioral effects of rimcazole analogues alone and in combination with cocaine.

Authors:  Jonathan L Katz; Therissa A Libby; Theresa Kopajtic; Stephen M Husbands; Amy Hauck Newman
Journal:  Eur J Pharmacol       Date:  2003-05-09       Impact factor: 4.432

View more
  14 in total

1.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

2.  Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects.

Authors:  Weimin C Hong; Michael J Wasko; Derek S Wilkinson; Takato Hiranita; Libin Li; Shuichiro Hayashi; David B Snell; Jeffry D Madura; Christopher K Surratt; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2018-06-26       Impact factor: 4.030

3.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

Review 4.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

5.  Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.

Authors:  Jacqueline D Keighron; Juliana C Quarterman; Jianjing Cao; Emily M DeMarco; Mark A Coggiano; Apre Gleaves; Rachel D Slack; Claudio Zanettini; Amy Hauck Newman; Gianluigi Tanda
Journal:  ACS Chem Neurosci       Date:  2019-01-31       Impact factor: 4.418

6.  Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist.

Authors:  Rajeev I Desai; David K Grandy; Carl R Lupica; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

7.  Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats.

Authors:  Takato Hiranita; Stephen J Kohut; Paul L Soto; Gianluigi Tanda; Theresa A Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

8.  Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.

Authors:  Rejwi Acharya Dahal; Akula Bala Pramod; Babita Sharma; Danielle Krout; James D Foster; Joo Hwan Cha; Jianjing Cao; Amy Hauck Newman; John R Lever; Roxanne A Vaughan; L Keith Henry
Journal:  J Biol Chem       Date:  2014-08-31       Impact factor: 5.157

9.  2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Authors:  Takato Hiranita; Derek S Wilkinson; Weimin C Hong; Mu-Fa Zou; Theresa A Kopajtic; Paul L Soto; Carl R Lupica; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2014-02-11       Impact factor: 4.030

Review 10.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.